Allergic reactions to vitamin B12 are rare, but real. The reason may sound strange, but it's true - an allergy to cobalt.

Edesa anticipates topline results could be available within as few as 12 to 18 months following regulatory clearance by the FDA. Health Canada has previously granted approval to initiate this Phase 2 ...

With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for Incyte in a research note issued to investors on Monday, February 10th. William Blair analyst M.

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...